Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- BLA:
-
Biologics License Application
- BPSA:
-
BioProcess Systems Alliance
- CMO:
-
Contract manufacturing organization
- GMP:
-
Good manufacturing practice
- MAA:
-
Marketing Authorization Application
- ROW:
-
Rest of world
- WFI:
-
Water for injection
References
BioProcess Technology Consultants (2011) The State of Mammalian Cell Culture Biomanufacturing. BioProcess Technology Consultants, Inc. http://www.bptc.com/ECommerce/Reports. Accessed 31 Dec 2012
Norman P (2011) Monoclonal antibodies in the pipeline: a segment of major growth. Cambridge Healthtech Institute. http://www.insightpharmareports.com/monoclonalantibodiesreport. Accessed 31 Dec 2012
Visiongain (2011) Therapeutic monoclonal antibodies: world market 2011–2021. Visiongain LTD. http://www.visiongain.com/Report/685/Therapeutic-Monoclonal-Antibodies-World-Market-2011-2021. Accessed 31 Dec 2012
Ginsberg PL et al (2002) The road ahead for biologics manufacturing. U.S. Bancorp Piper Jaffray Equity Research
Molowa DT (2001) The state of biologics manufacturing. J.P. Morgan Securities Inc., New York
Molowa DT (2002) The state of biologics manufacturing: part 2. J.P. Morgan Securities Inc., New York
Diamasi JA et al (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151–185
Pavlou AK, Reichert JM (2004) Recombinant protein therapeutics-success rates, market trends and values to 2010. Nat Biotechnol 22(12):1513–1519
Algra D (2002) Dealing with the capacity crunch in biopharma. Presented at bioLOGIC2002, 5–7 June 2002, Geneva
Downey W (2008) Biopharma CMO market report. Contract Pharma 10(4):58–63
Liu C, Downey W (2010) State of the Bio-CMO market. Contract Pharma 12(3):54–59
Soiron R (2011) Lonza 2011 full year results—25 January 2012. Lonza Group Ltd. http://www.lonza.com/~/media/Assets/about-lonza/Investor%20Information%20-%20All%20Reports%20Presentation/20120125FYR.ashx. Accessed 31 Dec 2012
Boehringer Ingelheim GmbH (2011) Corporate Magazine 2011 annual report. Boehringer Ingelheim GmbH. http://www.boehringer-ingelheim.com/content/dam/internet/opu/com_EN/document/01_news/08_APC/APC_2012/BoehringerIngelheim_Annual_Report_2011_complete.pdf. Accessed 31 Dec 2012
Downey W (2012) Bio-CMO industry trends. Contract Pharma 14(4):70–75
Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Office of Regulatory Affairs (US) (2008) Guidance for industry—cGMP for phase I investigational drugs. Department of Health and Human Services. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070273.pdf. Accessed 31 Dec 2012
Reynolds EB (2011) The changing geography of biomanufacturing. The Industrial Performance Center, Massachusetts Institute of Technology. http://web.mit.edu/ipc/publications/pdf/IPC11-001.pdf. Accessed 31 Dec 2012
Machulski J (2002) Case study of Lonza’s 20,000 L cell culture facility project. Presented at Barnett international’s biomanufacturing conference, 30 Sept 2002–1 Oct 2002, Boston, MA
Stout J (2011) Shire’s manufacturing strategy and new flexible facility. Presented at International Business Communication Life Sciences’ Seventh international biopharmaceutical manufacturing and development summit, 12–14 Sept 2011, San Diego, CA
Ciambrone B (2011) Bravely deploying single use technologies at commercial scale. Presented at International Business Communication Life Sciences’ Eighth international single-use applications for biopharmaceutical manufacturing conference, 6–8 June 2011, Boston, MA
Jones SD, Ransohoff TC (2011) Single use products for bioproduction: available options for cell culture and downstream processing. Am Pharm Rev 14(4):12–20
Roebers JR (2009) Future trends in biopharmaceutical operations and facilities. Presented at International Business Communications Life Sciences’ Bioprocess international conference, 12–16 Oct 2009, Raleigh, NC
Hodge G (2004) Disposable components enable a new approach to biopharmaceutical manufacturing. BioPharm Int 17(3):38–49
Fromison J (2009) Disposables in clinical manufacturing. Am Pharm Rev 12(2):20–27
Ransohoff TC (2011) Manufacturing capacity trends and disposable technologies. Presented at the World Antibody Manufacturing and Development Summit, Pre-conference workshop, 24 May 2011, Boston, MA
Levine HL (2009) Challenges and solutions for biopharmaceutical manufacturing. Presented at Cambridge HealthTech Institute, PepTalk conference, 14–20 Jan 2009, San Diego, CA
Steininger B (2008) Platform technology to accelerate drug discovery and development—a small company’s CMC approach to understand GDF biology. Presented at the International Society for Pharmaceutical Engineering’s 2008 annual meeting, 26–29 Oct 2008, Boca Raton, FL
Brodeur CM (2011) What’s next after achieving rapid capacity increase and flexibility through the use of disposables? Presented at International Business Communications Life Sciences’ Seventh international biopharmaceutical manufacturing and development summit, 12–14 Sept 2011, San Diego, CA
Singh V (1999) Disposable bioreactor for cell culture using wave-induced agitation. Cytotechnology 30(1–3):149–158
Eibl R et al (2010) Disposable bioreactors: the current state-of-the-art and recommended applications in biotechnology. Appl Microbiol Biotechnol 86(1):41–49
Robinson JM (2009) An alternative to the scale-up and distribution of pandemic influenza vaccine. Biopharm Int 22(Suppl):12–20
Noe W (2011) A brief review on evolving cell culture based manufacturing processes & technology drivers over the past 25 years. Presented at Cambridge Healthtech Institute’s Peptalk conference, 13–17 Jan 2011, San Diego, CA
Smelko JP et al (2011) Performance of high intensity fed-batch mammalian cell cultures in disposable bioreactor systems. Biotechnol Prog 27(5):1358–1364
Craig J, Bhella R (2011) A step towards standardizing films for single-use bioprocessing vessels. BioProcess Int 9(Suppl 2):42–46
Whitford W (2011) Improving process monitoring capabilities in SUB bioprocess development. Presented at International Business Communications Life Sciences’ Antibody development and production week, 16–18 March 2011, Bellevue, WA
ATMI, Inc. (2011) ATMI announces helium integrity testing for single-use bioprocess vessels. ATMI, Inc. http://files.shareholder.com/downloads/ATMI/1541192980x0x455083/3d94c718-a252-4e70-af65-373dea6e24bb/ATMI_News_2011_3_29_General_Releases.pdf. Accessed 31 Dec 2012
Ransohoff TC (2012) The use of disposable technologies in biopharmaceutical purification processes. Presented at American Association of Pharmaceutical Scientists’ annual meeting and exposition, 14–18 Oct 2012, Chicago, IL
Pollard D (2012) Extracting the full potential of single use. Presented at International Business Communication Life Sciences’ Ninth annual single-use applications for biopharmaceutical manufacturing conference, 14–16 June 2012, San Francisco, CA
Lee EK (2010) Single-use technologies in biologics and vaccines manufacturing industries. Presented at the fourth national conference on clinical research vaccines and biologics summit 2010, 4 June 2010, Kuala Lumpur, Malaysia
GE Healthcare Life Sciences (2012) GE Healthcare launches modular biopharmaceutical factory, KUBio. GE Healthcare Life Sciences. http://www.genewscenter.com/Press-Releases/GE-Healthcare-launches-modular-biopharmaceutical-factory-KUBio-3ac1.aspx. Accessed 31 Dec 2012
Sinclair A et al (2008) The environmental impact of disposable technologies. BioPharm Int 21(Suppl 11):S4–S11
Rawlings B, Pora H (2009) Environmental impact of single-use and reusable bioprocess systems. Bioprocess Int 7(2):18–25
Pora H, Rawlings B (2009) Managing solid waste from single-use systems in biopharmaceutical manufacturing. Bioprocess Int 7(1):18–25
Disposables Subcommittee of the Bio-Process Systems Alliance (2007) Guide to disposal of single-use bioprocess system. Bioprocess Int 5(11):22–28
Hagen B (2011) CMO management: resolving problems, mitigating risks, and capturing opportunities. Presented at the International Quality and Productivity Center’ 12th contract manufacturing for pharmaceuticals and biotech conference, 23–25 May 2011, Berkeley, CA
Wright R (2011) Buttoning down the pharma supply chain. Life Science Leader. http://www.lifescienceleader.com/magazine/past-issues3/item/3628-buttoning-down-the-pharma-supply-chain. Accessed 31 Dec 2012
Darnell JR (2010) Time to revisit supplier quality management. BioPharm Int 25(11):18–20
Martin J (2011) Single-use technology-balancing the risks and rewards. BioPharm Int 24(Suppl):22–25
Steininger B (2011) Challenges in using single-use systems for pilot development and GMP process. Presented at International Business Communications Life Sciences’ Eighth international single-use applications for biopharmaceutical manufacturing conference, 6–8 June 2011, Boston, MA
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ecker, D.M., Ransohoff, T.C. (2013). Mammalian Cell Culture Capacity for Biopharmaceutical Manufacturing. In: Zhou, W., Kantardjieff, A. (eds) Mammalian Cell Cultures for Biologics Manufacturing. Advances in Biochemical Engineering/Biotechnology, vol 139. Springer, Berlin, Heidelberg. https://doi.org/10.1007/10_2013_215
Download citation
DOI: https://doi.org/10.1007/10_2013_215
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-54049-3
Online ISBN: 978-3-642-54050-9
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)